Latest Monoclonal antibody therapy Stories
Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio,
MONROVIA, Calif., March 28, 2014 /PRNewswire/ -- Xencor, Inc.
CAMBRIDGE, England, March 16, 2014 /PRNewswire/ -- Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust
SAN DIEGO, March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration
AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- XBiotech announced today that the United States Patent and Trademark Office (USPTO) granted another key patent to support the Company's growing
DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/885sfr/bispecific ) has announced the addition of the "Concise Analysis
Gallus BioPharmaceuticals, LLC, a premier pure-play biologics contract manufacturing organization has signed a manufacturing agreement with Symphogen, A/S, a private biopharmaceutical company
- BioMotiv Establishes Kodosil Bio to Develop Collaboration Compounds - SAN DIEGO and CLEVELAND, Feb.
BURNABY, BC, Feb.
SAN DIEGO, Jan.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.